AR089771A1 - Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 - Google Patents

Derivados de bencil sulfonamida utiles como inhibidores de mogat-2

Info

Publication number
AR089771A1
AR089771A1 ARP130100180A ARP130100180A AR089771A1 AR 089771 A1 AR089771 A1 AR 089771A1 AR P130100180 A ARP130100180 A AR P130100180A AR P130100180 A ARP130100180 A AR P130100180A AR 089771 A1 AR089771 A1 AR 089771A1
Authority
AR
Argentina
Prior art keywords
mogat
bencil
inhibitors
derivatives
useful
Prior art date
Application number
ARP130100180A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47148691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089771(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR089771A1 publication Critical patent/AR089771A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Abstract

Estos compuestos son útiles para tratar la hipertrigliceridemia. Reivindicación 1: Un compuesto de conformidad con la fórmula (1) caracterizado porque R¹ se selecciona de: -CH₃ y -CF₃; R² se selecciona de: H, -CH₃, -CH₂OCH₃, y -CH₂OCH₂CH₃; R³ se selecciona de: H, alquilo C₁₋₂, -CH₂OCH₃, -CH₂OCH₂CH₃; R⁴ se selecciona de: H, halo, y -OCH₃; R⁵ se selecciona de H y halo; A se selecciona de: CH, C-F, C-CN, y N; X se selecciona de: CH, C-F, C-OCH₃, y N; y siempre que solamente uno de X y A sea N; o una sal del mismo farmacéuticamente aceptable.
ARP130100180A 2012-01-31 2013-01-21 Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 AR089771A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261592717P 2012-01-31 2012-01-31
EP12382432 2012-11-06

Publications (1)

Publication Number Publication Date
AR089771A1 true AR089771A1 (es) 2014-09-17

Family

ID=47148691

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100180A AR089771A1 (es) 2012-01-31 2013-01-21 Derivados de bencil sulfonamida utiles como inhibidores de mogat-2

Country Status (27)

Country Link
US (1) US8575352B2 (es)
EP (1) EP2809651B1 (es)
JP (1) JP2015511232A (es)
KR (1) KR20140106750A (es)
CN (1) CN104066719B (es)
AP (1) AP2014007794A0 (es)
AR (1) AR089771A1 (es)
AU (1) AU2013215468A1 (es)
BR (1) BR112014018636A8 (es)
CA (1) CA2859995A1 (es)
CL (1) CL2014001861A1 (es)
CO (1) CO7010839A2 (es)
CR (1) CR20140322A (es)
DO (1) DOP2014000178A (es)
EA (1) EA201491276A1 (es)
ES (1) ES2590929T3 (es)
GT (1) GT201400167A (es)
HK (1) HK1199025A1 (es)
IL (1) IL233712A0 (es)
MA (1) MA35886B1 (es)
MX (1) MX2014008599A (es)
PE (1) PE20141679A1 (es)
PH (1) PH12014501711A1 (es)
SG (1) SG11201404106QA (es)
TW (1) TW201343629A (es)
WO (1) WO2013116075A1 (es)
ZA (1) ZA201404836B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
PE20141789A1 (es) 2012-01-31 2014-11-19 Lilly Co Eli Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2
JP2016501844A (ja) 2012-11-06 2016-01-21 イーライ リリー アンド カンパニー ＭｏＧＡＴ−２阻害剤として有用な新規のベンジルスルホンアミド化合物
ES2879826T3 (es) 2015-06-15 2021-11-23 Nmd Pharma As Compuestos para su uso en el tratamiento de trastornos neuromusculares
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US20220135577A1 (en) 2019-01-11 2022-05-05 Shionogi & Co., Ltd. Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655283A1 (en) * 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP1659113A1 (en) * 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EA200701035A1 (ru) * 2004-11-10 2007-10-26 Пфайзер Инк. Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
KR20090051778A (ko) * 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
US8232282B2 (en) * 2006-09-28 2012-07-31 Dainippon Sumitomo Pharma Co., Ltd. Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same
WO2008059335A1 (en) * 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
EP2219646A4 (en) * 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
WO2010095767A1 (en) * 2009-02-23 2010-08-26 Banyu Pharmaceutical Co.,Ltd. Pyrimidin-4(3h)-one derivatives
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
PE20141789A1 (es) 2012-01-31 2014-11-19 Lilly Co Eli Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2

Also Published As

Publication number Publication date
TW201343629A (zh) 2013-11-01
IL233712A0 (en) 2014-09-30
AU2013215468A1 (en) 2014-07-10
HK1199025A1 (en) 2015-06-19
DOP2014000178A (es) 2014-08-31
BR112014018636A2 (es) 2017-06-20
PH12014501711A1 (en) 2014-10-13
ZA201404836B (en) 2017-08-30
MA35886B1 (fr) 2014-12-01
MX2014008599A (es) 2014-08-22
CO7010839A2 (es) 2014-07-31
WO2013116075A1 (en) 2013-08-08
BR112014018636A8 (pt) 2017-07-11
CA2859995A1 (en) 2013-08-08
EP2809651B1 (en) 2016-06-29
US8575352B2 (en) 2013-11-05
CL2014001861A1 (es) 2014-11-07
AP2014007794A0 (en) 2014-07-31
CR20140322A (es) 2014-08-25
GT201400167A (es) 2015-05-28
EA201491276A1 (ru) 2014-10-30
KR20140106750A (ko) 2014-09-03
ES2590929T3 (es) 2016-11-24
CN104066719B (zh) 2016-08-24
PE20141679A1 (es) 2014-11-08
EP2809651A1 (en) 2014-12-10
US20130197039A1 (en) 2013-08-01
CN104066719A (zh) 2014-09-24
JP2015511232A (ja) 2015-04-16
SG11201404106QA (en) 2014-08-28

Similar Documents

Publication Publication Date Title
AR089771A1 (es) Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
AR102977A1 (es) Inhibidores de erk
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
AR093759A1 (es) Dihidropiridona p1 como inhibidores del factor xia
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CR20150018A (es) Inhibidores macrocíclicos de virus flaviviridae
AR101558A1 (es) Difluoropirrolidinas como moduladores del receptor de orexina
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
EA201401081A1 (ru) Циклические амиды в качестве ингибиторов метар-2
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
CU24385B1 (es) Compuestos éteres de arilo útiles para tratar cancer de célula renal
CR20120417A (es) Inhibidores de virus flaviviridae
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
AR091431A1 (es) Compuestos de acido dimetil-benzoico
EA201690172A1 (ru) Полиморф ингибиторов syk
AR097866A1 (es) Derivados de 4-azaindol
EA201300442A1 (ru) ПИРРОЛИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ MetAP-2
AR107428A1 (es) COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
AR091770A1 (es) Indolcarbonitrilos moduladores selectivos de receptores androgenicos
AR088297A1 (es) R(+)-n-formil-propargil-aminoindano
AR091773A1 (es) Inhibidores de la histona desacetilasa y composiciones y sus metodos de uso
DOP2014000177A (es) Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2

Legal Events

Date Code Title Description
FB Suspension of granting procedure